



JFW

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/674,481
	Filing Date	September 30, 2003
	First Named Inventor	Wendy Corbett
	Art Unit	1614
	Examiner Name	
Total Number of Pages in This Submission	Attorney Docket Number	21271 US1

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Cited Art Search Report	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Eileen M. Ebel
Signature	
Date	June 15, 2004

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Eileen M. Ebel		
Signature		Date	June 15, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Wendy Lea Corbett

Group: 1614

Serial No. 10/674,481, filed September 30, 2003

Examiner:

For: **INDOLE-3-CARBOXAMIDES AS GLUCOKINASE ACTIVATORS**

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110
June 15, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents B4–B6 listed on Form PTO-1449 are enclosed.

Document B4, which is not written in the English language, corresponds to Document B6.


Enclosed is a Search Report, dated March 19, 2004, which was issued by the European Patent Office in the PCT/EP 03/10776 application corresponding to the captioned application. The Search Report lists Documents B4-B5.

Consideration of all the documents cited on Form PTO-1449 is requested.

Serial No. 10/674,481
Filed: September 30, 2003

Since the Information Disclosure Statement is submitted before receipt of the first Office Action on the merits for the above application and/or because each item of information contained in the Information Disclosure Statement was cited in a communication for the first time from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement, no fee is due. A Statement under 37 CFR §1.97(e) is enclosed.

Respectfully submitted,



Attorney for Applicant(s)
Eileen M. Ebel
(Reg. No. 37316)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-4391
Telefax: (973) 235-2363

142198



PATENT APPLICATION

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Wendy Lea Corbett

Group: 1614

Serial No. 10/674,481 filed September 30, 2003

Examiner:

For: **INDOLE-3-CARBOXAMIDES AS GLUCOKINASE ACTIVATORS**

STATEMENT UNDER 37 CFR §1.97(e)

Nutley, New Jersey 07110
June 15, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

I hereby certify:

X That each item of information contained in the enclosed information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this information disclosure statement.

— That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the statement.

Respectfully submitted,


Attorney for Applicant(s)
Eileen M. Ebel
(Reg. No. 37316)
340 Kingsland Street
Nutley, NJ 07110
Telephone: (973) 235-4391
Telefax: (973) 235-2363

JUN 18 2004

(Use several sheets if necessary)

Sheet: ARK 01	of	1
---------------	----	---

Application Number	10/674,481
Filing Date	September 30, 2003
First Name Inventor	Wendy Lea Corbett
Group Art Unit	
Examiner Name	
Attorney Docket Number	21271 US1

[illegible]

Examiner Initials'	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T*
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
	B4	WO 02 53534			Daiichi Pharma	07-11-2002	
	B5	WO 03 106462			Pfizer	12-24-2003	
	B6	EP 1346982			Daiichi Pharma	09-24-2003	
Examiner Signature		Date Considered					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹For the next citation designation to appear.

²Unique citation designation number. ³See attached Kinds of U.S. Patent Documents. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation or abstract is attached.